theMednetRegister
Lancet Oncol 2016 Aug
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.   

Related Questions

Can any non-SBRT hypo fractionation regimen for prostate cancer be regarded as the new standard of care, or as an equal alternative standard of care?
New answer by Radiation Oncologist at Brigham and Women's Hospital (September 2, 2016)
RTOG 04-15 (N = 1092) – W Robert Lee et al. Disease state: Low risk PC Randomization:  73.8 Gy RT in 1.8 Gy fx’s versus 70 Gy RT in 2.5 Gy fx&rsqu...
Is it appropriate to use moderate hypofractionation for the treatment of patients with high-risk prostate cancer?
New comment by Radiation Oncologist at Jacob E Locke MD PA ( January 30, 2022)
It is a standard perhaps but not the* standard as the trial paper concludes that "no significant overall survival difference was observed between the treatment arms." Extrapo...
When you do recommend conventional fractionation over moderate hypofractionation for prostate cancer?
Do you prefer to treat patients with factors such as large prostate volume, significant comorbidities, anticoagulation use, history of TURP, or high A...
New answer by Radiation Oncologist at Fox Chase Cancer Center (May 15, 2021)
At Fox Chase, the overwhelming majority of our prostate patients who are treated with IMRT are treated with some form of hypofractionation (moderate hypofx or SbRT). Based on ...
What dose do you prescribe when treating the prostate in patients with low metastatic burden and what are your dose constraints?
The STAMPEDE trial recently published in Lancet used 55 Gy in 20 fractions but did not include dose constraints.
New comment by Radiation Oncologist at Lake Huron Medical Center ( February 25, 2021)
60 Gy in 20 fractions, as well.
Can SBRT be considered for high risk prostate cancer?
Prospective single arm studies with short term follow-up were recently presented in abstract form (Kishan et al, IJROBP, Oct 2017; Mallick et al, IJRO...
New answer by Radiation Oncologist at The Oregon Clinic-Radiation Oncology West (October 23, 2020)
I agree 100% with Dr. @Amar U. Kishan. We shouldn't substitute an investigational option off-trial when we already have multiple effective, safe options. My hope is that SBRT ...
When do you consider elective pelvic nodal irradiation for unfavorable intermediate risk prostate cancer?
Do you use decipher, or other genetic testing to determine whether you will include pelvic lymph nodes when you give definitive EBRT? Can you comment ...
New comment by Radiation Oncologist at University of Florida ( June 19, 2024)
I’m risk averse. 10% or higher, I’d treat mine.
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
If delivering 300 cGy per fraction to the DIL, what urethra dose constraints to you use for 26 and 28 fraction regimens?
New comment by Radiation Oncologist at M.D. Anderson Cancer Center ( August 29, 2024)
Always appreciate your thoughtful and detailed responses @Krishnan! 
Copyright © 2024 theMednet
All Rights Reserved.